GNC Board Includes Sale In Menu For Financial, Strategic Overhaul
This article was originally published in The Tan Sheet
Executive Summary
The wellness and nutritional product manufacturer and retailer's board has "commenced a review of a wide range of strategic and financial alternatives to increase shareholder value." The board's review will include looking at accelerating the firm's already-launched refranchising initiative.
You may also be interested in...
GNC 'Broken Business' Repair: Single-Tier Pricing, Free Loyalty Program
Interim CEO Robert Moran says "we found … a badly broken business in need of change" since he took the helm in July. The broken parts include a loyalty program not driving sales; inconsistent and confusing pricing; and point-of-sale checkout failures.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.